Сравнение

Icatibant vs. Linaclotid

Два пептида рядом — идентичность, доказательная база, правовой статус и известные нежелательные явления.

Идентичность

Категория

Исследования (прочее)

Номер CAS

138614-30-9

851199-59-2

Молекулярная масса

1304.52 g/mol

1526.74 g/mol

Период полувыведения

нет данных

Последовательность

нет данных

Механизм действия

Icatibant

Icatibant competitively blocks the bradykinin B2 receptor. Because bradykinin mediates the vascular permeability, swelling and pain typical of hereditary angioedema, the blockade interrupts the acute attack.

Linaclotid

Linaclotide activates the guanylate cyclase-C receptor on the luminal surface of the intestinal epithelium. This raises cyclic GMP (cGMP), increases secretion of chloride and bicarbonate into the lumen, raises stool fluid content and accelerates transit; pain signaling is also modulated.

Доказательная база

Наивысшая доказательность

РКИ на людях

Исследования

из них на людях

Зафиксированные эффекты

Открытые противоречия

Задокументированные нежелательные явления

Правовой статус

Country	Icatibant	Linaclotid
Германия	Рецептурный	Рецептурный
США	Рецептурный	Рецептурный

Полные записи

Frequently asked questions

What is the difference between Icatibant and Linaclotid?: Icatibant is classified as "Исследования (прочее)", while Linaclotid is classified as "Исследования (прочее)". Icatibant: Icatibant is a synthetic decapeptide and selective antagonist of the bradykinin B2 receptor. It is approved to treat acute attacks of hereditary angioedema (HAE). Linaclotid: Linaclotide is a 14-amino-acid peptide and guanylate cyclase-C (GC-C) agonist. It is approved for irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation (CIC). This page contrasts both neutrally and source-based — with no usage or dosing recommendation.
Which peptide is better supported by science, Icatibant or Linaclotid?: The highest available evidence level is "РКИ на людях" for Icatibant and "РКИ на людях" for Linaclotid. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.
What is the legal status of Icatibant and Linaclotid in Germany and the United States?: Германия: Icatibant — Рецептурный, Linaclotid — Рецептурный. США: Icatibant — Рецептурный, Linaclotid — Рецептурный. These are factual summaries with source and review date on the individual pages.

Country

Icatibant

Linaclotid

Германия

Рецептурный

США

Рецептурный

Frequently asked questions

What is the difference between Icatibant and Linaclotid?

Icatibant is classified as "Исследования (прочее)", while Linaclotid is classified as "Исследования (прочее)". Icatibant: Icatibant is a synthetic decapeptide and selective antagonist of the bradykinin B2 receptor. It is approved to treat acute attacks of hereditary angioedema (HAE). Linaclotid: Linaclotide is a 14-amino-acid peptide and guanylate cyclase-C (GC-C) agonist. It is approved for irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation (CIC). This page contrasts both neutrally and source-based — with no usage or dosing recommendation.

Which peptide is better supported by science, Icatibant or Linaclotid?

The highest available evidence level is "РКИ на людях" for Icatibant and "РКИ на людях" for Linaclotid. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.

What is the legal status of Icatibant and Linaclotid in Germany and the United States?

Германия: Icatibant — Рецептурный, Linaclotid — Рецептурный. США: Icatibant — Рецептурный, Linaclotid — Рецептурный. These are factual summaries with source and review date on the individual pages.